Your browser doesn't support javascript.
loading
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé, Yael P; Fox, Elizabeth; Teachey, David T; Reid, Joel M; Safgren, Stephanie L; Carol, Hernan; Lock, Richard B; Houghton, Peter J; Smith, Malcolm A; Hall, David; Barkauskas, Donald A; Krailo, Mark; Voss, Stephan D; Berg, Stacey L; Blaney, Susan M; Weigel, Brenda J.
Affiliation
  • Mossé YP; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Pennsylvania. mosse@chop.edu.
  • Fox E; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Teachey DT; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Pennsylvania.
  • Reid JM; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Safgren SL; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Pennsylvania.
  • Carol H; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Lock RB; Mayo Clinic, Rochester, Minnesota.
  • Houghton PJ; Mayo Clinic, Rochester, Minnesota.
  • Smith MA; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
  • Hall D; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
  • Barkauskas DA; Greehey Children's Cancer Research Institute, University of Texas Health Science Center San Antonio, San Antonio, Texas.
  • Krailo M; Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland.
  • Voss SD; Children's Oncology Group, Monrovia, California.
  • Berg SL; Children's Oncology Group, Monrovia, California.
  • Blaney SM; Department of Preventive Medicine, University of Southern California, Los Angeles, California.
  • Weigel BJ; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Clin Cancer Res ; 25(11): 3229-3238, 2019 06 01.
Article in En | MEDLINE | ID: mdl-30777875
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Azepines / Leukemia / Protein Kinase Inhibitors / Neoplasms / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Azepines / Leukemia / Protein Kinase Inhibitors / Neoplasms / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: Estados Unidos